Schizophrenia Bulletin Advance Access originally published online on November 10, 2005
Schizophrenia Bulletin 2006 32(1):30-36; doi:10.1093/schbul/sbj023
© The Author 2005. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org.
Ethical Concerns in Schizophrenia Research: Looking Back and Moving Forward
Scott T Wilson23, and
Barbara Stanley1,24,
2 Department of Neuroscience, New York State Psychiatric Institute
3 Department of Psychiatry, Columbia University College of Physicians & Surgeons
4 Department of Psychology, John Jay College, City University of New York
| The first 150 words of the full text of this article appear below. |
 |
Introduction
|
|---|
Over the past two decades, the debate over the ethical issues
involved in schizophrenia research has evolved considerably
in some, but not all, respects. In general, discussions about
the most important of these issues have been propelled by developments
both in our understanding of schizophrenia and within the field
of psychiatry itself, as well as in tandem with the evolution
of standards for the protection of human research participants.
Although new scientific developments, particularly those having
occurred over the last decade, have required researchers to
consider new and increasingly complicated ethical conundrums,
there are also many issues from years past that remain only
partially resolved.
The larger debate on the ethics of experimentation with human subjects essentially began during the postWorld War II period with the Nuremburg trials, as the world learned about the experimentation committed by the Nazis on unwilling human subjects. The Nuremburg Code, issued in 1947, was . . . [Full Text of this Article]
 |
Competency and Informed Consent
|
|---|
 |
Exclusion of Suicidal Patients in Research
|
|---|
 |
Medication Withdrawal and Medication-Free Research
|
|---|
 |
Early Intervention Protocols
|
|---|
 |
Genetic Studies of Schizophrenia
|
|---|
 |
Conclusions
|
|---|
1To whom correspondence should be addressed; Department of Neuroscience, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 42, New York, New York 10032; tel: 212 543. 5918, fax: 212 543 6946, e-mail: bhs2@columbia.edu.

CiteULike
Connotea
Del.icio.us What's this?